Fovista®, a once-promising experimental drug for treatment of wet macular degeneration, has failed to show positive results in Phase 3 trials. This is surprising, since, on June 14, 2012, Ophthotech Corporation reported a 62% higher relative visual benefit when Fovista (1.5 mg) was used in combination with Lucentis in Phase 2b clinical trials.
Based upon those results, Ophthotech enrolled 1,243 patients in Phase 3 trials at hundreds of centers worldwide. The company expected to have positive top-line data from the clinical program available in 2016. The results, however, have shown no significant improvement in vision from the combination therapy compared with Lucentis injection alone.
“We are very disappointed in the results from these trials, particularly for patients afflicted with wet AMD,” commented David R. Guyer, M.D., Chief Executive Officer of Ophthotech. “We are thankful to the patients and clinical investigators and their staff for participating in the trials. We will continue to analyze the data from these two studies to better understand the trial results.”
Source: Ophthotech Corporation